Navigation Links
Lycera Announces Milestone in Merck Collaboration
Date:3/25/2015

NEW YORK and ANN ARBOR, Mich., March 25, 2015 /PRNewswire/ -- Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.  The program, announced in February 2013, is focused on discovering and developing small molecule therapeutic candidates directed to selected novel targets being investigated for the treatment of a broad range of immune-mediated disorders.

"We are pleased to announce the achievement of this milestone with our collaborator Merck," stated Lycera's President and CEO Paul Sekhri.  "The progress of the program provides further validation of Lycera's leadership in modulating immune responses to treat diverse disease indications with compelling unmet needs."

Under the terms of the previously announced agreement, Lycera received an upfront payment and research funding, and is eligible to receive in excess of $300 million in research, development, regulatory and commercial milestone payments.  Merck is responsible for clinical development and has worldwide marketing and commercialization rights to any products that may be developed as a result of the collaboration.  Lycera is entitled to receive royalty payments, as well as development and sales milestones, on global sales from any such products.  Further details of the financial terms were not disclosed.

The collaboration builds on an original agreement between Merck and Lycera, announced in March 2011, that is focused on therapies targeting inhibitors of the retinoic acid related orphan receptor (RORγt), the key transcription factor coordinating both differentiation of T-helper 17 (Th17) cells and production of highly pro-inflammatory mediators such as interleukin-17 (IL-17).

About Lycera
Lycera is a biopharmaceutical company developing novel oral immune modulators for the treatment of cancer and autoimmune diseases.  Based on successful progress of its world-class R&D platform, including expertise in immune metabolism, cell signaling, and immune cell differentiation, Lycera is commencing multiple clinical programs in 2015 and 2016.  Lead efforts are advancing oral RORγ agonists for diverse applications in immune-oncology, and an oral, selective ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease.  In addition, Lycera has established two collaborations with Merck to discover, develop and commercialize small molecule therapies for autoimmune disorders.  Lycera's leadership possesses deep experience in drug discovery, development, and commercialization and has established close relationships with renowned thought leaders and clinical researchers worldwide.  Lead investors in Lycera include InterWest Partners, ARCH Venture Partners, Clarus Ventures, and EDF Ventures.  For more information on Lycera, please visit www.lycera.com.

Contacts:

For Media:
Justin Jackson, Burns McClellan, on behalf of Lycera Corp.
212-213-0006, ext. 327
jjackson@burnsmc.com


'/>"/>
SOURCE Lycera Corp.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Lycera to Present at the 2015 American Association for Cancer Research (AACR) Annual Meeting
2. Lycera Announces Research Showing Promising Anti-Cancer Activity of Novel, Oral Immunotherapy Candidates
3. Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting
4. TruHearing Announces Addition of Jack Friedman to Board of Directors
5. InBody Announces Important Revision to Body Composition Analysis CPT Code
6. Intellirod Spine Announces Key Licensing Milestone in Development of Novel Spinal Sensor
7. Teikoku Pharma USA Announces New Drug Application to The U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula
8. TB Alliance Announces Partnership with U.S. Fund for UNICEF to Increase Access to Impending New Child-Friendly TB Treatments
9. CoLucid Pharmaceuticals Announces Relocation of Company Headquarters to Massachusetts
10. Elsevier Announces Publishing Agreement with the International Society for Sexual Medicine
11. Kids v Cancer Announces "The Advancing Hope Act" To Reauthorize The Pediatric Priority Review Voucher Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2020)... ... 10, 2020 , ... A device that teaches toddlers to go to sleep ... sleep training system for children, launching today on Kickstarter. Hush Buddy creates and reinforces ... Sleep System, getting a child to sleep soundly is as easy as ready, read, ...
(Date:2/10/2020)... Ky. (PRWEB) , ... February 10, 2020 , ... ... partnership with Healthstat , a leading provider of onsite health clinics. Focused ... SaaS-based population health management software, Healthward ® at its onsite employee health ...
(Date:2/9/2020)... ... , ... Clarence Moses-EL allowed AYBOS to capture his former ... years of wrongful incarceration (Moses-EL was acquitted in 2016). AYBOS Communication Director calls ... in the compounded judicial trauma, destruction of evidence, inhumane treatment and disregard for ...
Breaking Medicine Technology:
(Date:2/11/2020)... ... February 11, 2020 , ... There are many reasons why ... but the service that truly raises us above our competitors is our true Peer ... a board-certified Radiologist with years of clinical experience. We understand that it is impossible ...
(Date:2/11/2020)... (PRWEB) , ... February 11, 2020 , ... The wait is finally over. The first ... Nordisk. For years, this squad has been associating professional sports to a truly special project. ... the world made up entirely of athletes with diabetes. They decided to take on the ...
(Date:2/11/2020)... N.C. (PRWEB) , ... February 11, 2020 , ... ... Meat Handbook Revised and Expanded Second Edition: From Sourcing to Butchery, Mindful Meat ... Meredith Leigh and published by New Society Publishers, this new version brings discussions ...
(Date:2/10/2020)... ... 2020 , ... R3 Medical Training is now enrolling for its PDO ... training consists of thread lift placement on real patients for the face, abdomen and ... an excellent alternative currently for nonoperative facelift. The procedures are safe, quick and with ...
(Date:2/10/2020)... (PRWEB) , ... February 10, 2020 , ... C. A. ... Marketing LLC. At the time he was still in the music business as a ... for AYBOS to create marketing campaigns for HNF, and HNF to create any music ...
Breaking Medicine News(10 mins):